comparemela.com

Latest Breaking News On - Harma biotech - Page 1 : comparemela.com

Biocon shares rise 2% after turning profitable in Q3

The company s revenue from operations increased by 34.4 percent to Rs 3,953.7 crore

Biocon biologicsNitin prabhakar shenoyNicholas robert haggarBiocon limitedIndependent directorPrabhakar shenoyDigital transformationStock market newsHarma biotech

Anteris Technologies Ltd appoints highly experienced chief medical officer

The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™.

Anteri durWayne patersonHarvard school of public healthBeth israel deaconess medical centerMedicine at duke universityHarvard medical schoolMasters in public healthInterventional cardiologistAdvisory boardAnteris medical advisory boardPublic healthClinical effectivenessHarvard schoolInternal medicineSmall capsTc markets quoted

Anteris Technologies Ltd extends manufacturing agreement with LeMaitre Vascular Inc for CardioCel™ and VascuCel™

Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.

Wayne patersonAnteri cardiocelLemaitre vascular incMaitre vascular incEuropean medical devices directorateSmall capsTc markets quotedOtcqb quotedHarma biotechAnteris technologies ltdSx avr

Faron Pharmaceuticals PLC right in middle of fight against cancer and Coronavirus

Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours

Deep diveHarma biotechFaron pharmaceuticals oyLon farn

CytoDyn reveals data from its final mTNBC report with its flagship drug leronlimab

CytoDyn Inc CEO Nader Pourhassan shared an update to its previously reported preliminary results from its Phase 1b/2 trials and compassionate use of.

Nader pourhassanCreatv microtech incCytodyn incProgression free survivalDirector interviewsHarma biotechCytodyn incOtcmkts cydy

vimarsana © 2020. All Rights Reserved.